Fineimmu

Executive Summary

Fineimmu is a private, preclinical-stage Chinese biotechnology company headquartered in Shanghai, founded in 2015. The company specializes in the discovery of novel antibody-based therapeutics targeting oncology and inflammatory diseases with high unmet medical need. By leveraging advanced antibody engineering, Fineimmu aims to develop candidates with unique mechanisms of action. Despite its small size (1–50 employees) and limited public disclosures, the company operates in a competitive landscape with significant opportunities in both cancer immunotherapy and autoimmune indications. The absence of disclosed pipeline assets, funding history, or valuation suggests an early stage of development, with a focus on internal research programs rather than clinical-stage assets. As such, the company's near-term value hinges on its ability to advance preclinical candidates toward IND-enabling studies and establish strategic partnerships to mitigate development risk.

Upcoming Catalysts (preview)

• Q3 2026Lead candidate selection for IND-enabling studies15% success
• Q1 2027Presentation of preclinical data at major conference30% success
• Q2 2027Potential partnering or licensing deal for key programs20% success